Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 9, 2007

Tripos Inks Library Analysis Agreement with Elan

  • Tripos Discovery Research (TDR) will assist Elan Pharmaceuticals in analyzing and enhancing the diversity of its small molecule screening collection.

    TDR will perform computational clustering of key subsets and determine optimal areas for expansion. The company also will provide high-throughput quality control analyses of legacy compounds via mass spectrometry.

    Applying its computational design and therapeutic medicinal chemistry tools, TDR says that it is able to reduce drug discovery timelines by up to 30%.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »